Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection / 中华流行病学杂志
Chinese Journal of Epidemiology
; (12): 362-365, 2003.
Article
en Zh
| WPRIM
| ID: wpr-348867
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To determine the efficacy of recombinant hepatitis B (rHB) vaccine and low-dose hepatitis B immune globulin (HBIG) in the prevention of mother-infant transmission of hepatitis B virus (HBV) infection.</p><p><b>METHODS</b>rHB vaccine was administered to two groups of healthy neonates born to mothers with both hepatitis B surface antigen and e antigen positive in Guangxi, Hunan and Hebei province. Two hundred eighty-nine subjects were included in active immunization group, receiving triple doses of rHB vaccine given i.m. at 0, 1 and 6 month intervals; while 186 subjects receiving 50 IU HBIG at birth with triple doses of rHB vaccine in the low-dose HBIG group.</p><p><b>RESULTS</b>Efficacy of active immunization alone was 87.8% (95% CI: 83.6 - 91.9). Efficacy of rHB vaccine and HBIG was 91.2% (95% CI: 86.7 - 95.6). No significant differences in efficacy by type of rHB vaccine (P = 0.707 2), immunoprophylaxis programs (P = 0.295 5) and regions of living (P = 0.998 7) were noticed. Seroprotection rates (anti-HBs >or= 10 mIU/ml) were detected in 91.1% and 93.5% in rHB vaccine alone recipients and rHB vaccine plus HBIG recipients, with geometric mean titer (GMT) of 153 mIU/ml and 164 mIU/ml at 1 year of age, respectively. Anti-rHBs decreased significantly with years after vaccination (chi(2) = 60.47, P = 0.000 1). Seroprotection rates of anti-rHBs antibodies decreased to 65.0% and 66.6% at 4 years of age in rHB vaccine alone recipients and rHB vaccine plus HBIG recipients, with GMT of 55 mIU/ml and 56 mIU/ml, respectively.</p><p><b>CONCLUSION</b>These results suggested that the effectiveness of rHB vaccine plus low-dose HBIG was much better than only active plasma-derived vaccine; however, methods used for anti-rHBs assay need to be evaluated and verified.</p>
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Inmunoglobulina G
/
Vacunas Sintéticas
/
China
/
Epidemiología
/
Esquemas de Inmunización
/
Vacunación
/
Vacunas contra Hepatitis B
/
Transmisión Vertical de Enfermedad Infecciosa
/
Alergia e Inmunología
/
Hepatitis B
Límite:
Female
/
Humans
/
Male
/
Newborn
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Chinese Journal of Epidemiology
Año:
2003
Tipo del documento:
Article